| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | ROIVANT SCIENCES LTD. CMN | Jan 27, 2026 | |
| Sell | Roivant Sciences Ltd. | Oct 31, 2025 | |
| Buy | Roivant Sciences Ltd. | Oct 30, 2025 | |
| Sell | Roivant Sciences Ltd. | Oct 30, 2025 | |
| Buy | Roivant Sciences Ltd. | Jun 17, 2025 |
This page tracks congressional stock trading activity in Roivant Sciences Ltd. (ROIV) in the Healthcare sector. Disclosed Capitol has indexed 5 disclosed congressional trades involving ROIV. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of March 2026 — Disclosed Capitol has tracked 5 disclosed congressional trades in Roivant Sciences Ltd. (ROIV) — 3:2 sell-heavy ratio — led by Lisa McClain (R).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Jan 27, 2026 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| Oct 31, 2025 | Lisa McClain | R | Sell | $1,001 - $15,000 |
| Oct 30, 2025 | Lisa McClain | R | Buy | $1,001 - $15,000 |
| Oct 30, 2025 | Lisa McClain | R | Sell | $1,001 - $15,000 |
| Jun 17, 2025 | Lisa McClain | R | Buy | $1,001 - $15,000 |
Across the 5 disclosed congressional trades in Roivant Sciences Ltd. (ROIV), members of Congress have reported 2 buys and 3 sells. The average 30-day alpha vs. the S&P 500 is -5.61%.
For fiscal year 2025, Roivant Sciences Ltd. reported revenue of $124.8M and net income of $4.35B, per SEC filings.
Most recent reported quarter: Q1 FY2026 — revenue $1.4M, net income -$189.8M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.